Observational studyBreast cancer research and treatment2026

Real-world second- and third-line progression-free survival after progression on first-line CDK4/6 inhibitors in HR+/HER2- metastatic breast cancer by PAM50 intrinsic subtype: the SOLTI-1801 CDK-PREDICT study.

Pablo Tolosa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.